Isthmus Partners LLC Buys 42,265 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Isthmus Partners LLC lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 34.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 165,247 shares of the medical equipment provider’s stock after purchasing an additional 42,265 shares during the period. Isthmus Partners LLC owned 0.36% of BioLife Solutions worth $35,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. 1620 Investment Advisors Inc. acquired a new stake in BioLife Solutions in the 2nd quarter valued at about $35,000. Register Financial Advisors LLC acquired a new stake in BioLife Solutions in the 1st quarter valued at about $96,000. Arizona State Retirement System acquired a new stake in BioLife Solutions in the 2nd quarter valued at about $217,000. State Board of Administration of Florida Retirement System acquired a new stake in BioLife Solutions in the 1st quarter valued at about $229,000. Finally, Legato Capital Management LLC acquired a new stake in BioLife Solutions in the 2nd quarter valued at about $233,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

BLFS has been the subject of several recent analyst reports. Craig Hallum raised their target price on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. TD Cowen upped their price objective on BioLife Solutions from $20.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. Northland Securities lifted their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. StockNews.com raised shares of BioLife Solutions to a “sell” rating in a report on Friday, May 10th. Finally, Benchmark raised shares of BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Monday, May 13th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus target price of $26.20.

BioLife Solutions Price Performance

BioLife Solutions stock traded down $0.94 during trading hours on Friday, reaching $23.79. 362,177 shares of the stock were exchanged, compared to its average volume of 386,486. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. BioLife Solutions, Inc. has a twelve month low of $8.92 and a twelve month high of $26.73. The company has a market cap of $1.10 billion, a P/E ratio of -16.75 and a beta of 1.85. The stock has a 50 day moving average of $23.34 and a two-hundred day moving average of $20.44.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.08. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. The business had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. Equities analysts expect that BioLife Solutions, Inc. will post -0.37 EPS for the current fiscal year.

Insider Transactions at BioLife Solutions

In related news, insider Sarah Aebersold sold 3,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $21.03, for a total value of $63,090.00. Following the sale, the insider now directly owns 61,683 shares of the company’s stock, valued at $1,297,193.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Sarah Aebersold sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $21.03, for a total value of $63,090.00. Following the completion of the transaction, the insider now owns 61,683 shares of the company’s stock, valued at $1,297,193.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Todd Berard sold 10,000 shares of BioLife Solutions stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $20.18, for a total value of $201,800.00. Following the transaction, the chief marketing officer now directly owns 108,894 shares in the company, valued at $2,197,480.92. The disclosure for this sale can be found here. 2.20% of the stock is owned by insiders.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.